| Literature DB >> 27135363 |
Yair Pozniak1, Nora Balint-Lahat2, Jan Daniel Rudolph3, Cecilia Lindskog4, Rotem Katzir5, Camilla Avivi2, Fredrik Pontén4, Eytan Ruppin6, Iris Barshack7, Tamar Geiger8.
Abstract
The genomic and transcriptomic landscapes of breast cancer have been extensively studied, but the proteomes of breast tumors are far less characterized. Here, we use high-resolution, high-accuracy mass spectrometry to perform a deep analysis of luminal-type breast cancer progression using clinical breast samples from primary tumors, matched lymph node metastases, and healthy breast epithelia. We used a super-SILAC mix to quantify over 10,000 proteins with high accuracy, enabling us to identify key proteins and pathways associated with tumorigenesis and metastatic spread. We found high expression levels of proteins associated with protein synthesis and degradation in cancer tissues, accompanied by metabolic alterations that may facilitate energy production in cancer cells within their natural environment. In addition, we found proteomic differences between breast cancer stages and minor differences between primary tumors and their matched lymph node metastases. These results highlight the potential of proteomic technology in the elucidation of clinically relevant cancer signatures.Entities:
Mesh:
Year: 2016 PMID: 27135363 DOI: 10.1016/j.cels.2016.02.001
Source DB: PubMed Journal: Cell Syst ISSN: 2405-4712 Impact factor: 10.304